Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What CAGR Is Anticipated for the Anti-Asthmatics And COPD Drugs Market Through 2029?

In recent years, the market size of peanut allergy treatments has witnessed a swift expansion. The market is projected to surge from $0.45 billion in 2024 to $0.5 billion in 2025, growing at a compound annual growth rate (CAGR) of 10.4%. The proliferation in the past period can be ascribed to factors such as a heightened frequency of peanut allergies, improvement in diagnostic tests, rising public consciousness and anxiety regarding the condition, and formulation of preemptive intervention strategies, in addition to the approval of regulatory bodies for peanut allergy treatments.

In the coming years, the market size for peanut allergy treatment is slated for a swift expansion. It’s projected to reach “$0.74 billion in 2029, with a compound annual growth rate (CAGR) of 10.2%. Potential factors for this growth during the forecast period include an ongoing increase in prevalence, the broader application of personalized medicine, the emergence of ground-breaking immunotherapy treatments, a surge in both public and private investments, and the spread of telemedicine services. Over the forecast period, key trends will likely encompass a higher usage rate of immunotherapy, advancements in biologic therapy, probiotic-based treatment integration, innovative technological solutions in delivery systems, tailored medicine practices, and regulatory endorsements and support.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15888&type=smp

What Market Forces Are Driving The Anti-Asthmatics And COPD Drugs Sector In 2025 And Beyond?

The market for anti-asthmatics and COPD drugs is heavily influenced by mutable risk factors, such as smoking, a sedentary lifestyle, and a poor nutritional regimen. Despite a worldwide downward trend in smoking, there’s a growing prevalence in developing nations like China, India, Indonesia, and Nigeria. For example, it’s anticipated that tobacco smokers will increase by 24 million in Indonesia and 7 million in Nigeria by 2025, and China accounts for over 40% of the global cigarette use. The risk of Asthma and COPD also rises with the consumption of fats, particularly saturated fatty acids, which is more prevalent in affluent nations such as the USA and Europe. According to the WHO, in these developed countries, more than 35% of the total energy requirement is derived from fats, compared to less than 20% in low-income nations, and under 25% in lower-middle-income countries.

The peanut allergy treatment market covered in this report is segmented –

1) By Drug Class: Antihistamines, Immunotherapies, Epinephrine, Other Drug Classes

2) By Route Of Administration: Injectable, Oral, Other Routes Of Administration

3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels

Subsegments:

1) By Antihistamines: Oral Antihistamines, Topical Antihistamines

2) By Immunotherapies: Oral Immunotherapy (OIT), Sublingual Immunotherapy (SLIT), Epicutaneous Immunotherapy (EPIT)

3) By Epinephrine: Epinephrine Auto-Injectors, Epinephrine Inhalers

4) By Other Drug Classes: Leukotriene Receptor Antagonists, Monoclonal Antibodies, Corticosteroids

What Future Market Trends Are Projected For The Anti-Asthmatics And COPD Drugs Industry?

Key players in the peanut allergy treatment market are shifting their attention towards the creation and advancement of biologic therapies, like anti-IgE monoclonal antibodies, with the goal of providing more precise and effective resolutions for managing peanut allergies, thereby enhancing patient outcomes and their quality of life. Anti-IgE monoclonal antibodies are a type of therapeutic compound designed to identify and nullify immunoglobulin E (IgE) antibodies in the human body. For example, in February 2024, Novartis Pharmaceuticals Corporation, a firm based in Switzerland, gained approval from the Food and Drug Administration (FDA) for a medication called Xolair (omalizumab). The medication is formulated to mitigate allergic reactions, including anaphylaxis, in patients aged 1 year and older suffering from IgE-related food allergies. The approval was supported by data from the NIH-backed Phase III OUtMATCH study, demonstrating a significant advancement in food allergy tolerance for patients undergoing treatment with Xolair in comparison to those administered a placebo.

Which Firms Are Considered Leaders In The Anti-Asthmatics And COPD Drugs Market Space?

Major companies operating in the peanut allergy treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Viatris Inc., Regeneron Pharmaceuticals Inc., Hikma Pharmaceuticals plc, ALK-Abelló A/S, Amneal Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc., Stallergenes Greer plc, kaleo Inc., Aquestive Therapeutics Inc., Vedanta Biosciences Inc., Aimmune Therapeutics Inc., AnaptysBio Inc., Alladapt Immunotherapeutics Inc., Aravax Pty Ltd., Intrommune Therapeutics Inc., IgGenix Inc., DBV Technologies SA, Camallergy Ltd., HAL Allergy Group, Prota Therapeutics Pty Ltd.

https://www.thebusinessresearchcompany.com/report/peanut-allergy-treatment-global-market-report

What Role Do Regional Policies And Investments Play In Anti-Asthmatics And COPD Drugs Market Expansion?

North America was the largest region in the peanut allergy treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peanut allergy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15888&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model